Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

November 10, 2017: By Jon Swedien

Second SightSecond Sight reported Nov. 2 that its Q3-2017 net sales totaled $1.6 million, compared with $1.2 million in the third quarter of 2016.

The Sylmar, California, developer of the Argus II retinal prosthesis said surgeons implanted 12 systems during the third quarter, compared with 19 in Q2-2017 and 14 in Q3-2016.

The Centers for Medicare and Medicaid Services (CMS) issued a final Medicare outpatient payment rate for 2018 of $122.5 thousand for the Argus II and the associated surgical implantation procedure, the company said. The 2017 reimbursement rate was $150 thousand, and the 2016 rate was $95 thousand.

Second Sight said it anticipates a strong Q4-2017, with more than 20 Argus II surgeries completed or scheduled as of Nov. 2.

For the first three quarters of 2017, Second Sight’s total revenues were $4.9 million compared with $3.3 million for the same period in 2016. This increase was mainly due to a higher number of implants and higher average revenues per implant in 2017 compared with the prior year, Second Sight said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023